Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.800 +0.130 (+3.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
News headline image
Cathie Wood Is Buying This Under-the-Radar AI Stock ↗
This company has massive upside potential, but that's not the whole story. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know ↗
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,... 
Via Benzinga
News headline image
Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report ↗
SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Where Will Recursion Pharmaceuticals Be in 5 Years? ↗
A lot is riding on whether its platform is valuable, or vaporware. 
Via The Motley Fool
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
News headline image
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
Company to host public L(earnings) Call on May 9 at 5:00 pm ET 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
The grant designates Altitude Lab as a top acceleration program for biotechnology startups 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves ↗
The $50 million purchase could turn into Nvidia's biggest investment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Top 3 Biotech Stocks to Buy in April 2024 ↗
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances. 
Via InvestorPlace
News headline image
3 Millionaire-Maker Biotech Stocks ↗
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
News headline image
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner' ↗
Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and CASY stocks rise. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals ↗
 
Via Benzinga
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
News headline image
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 ↗
Through opportunity for growth and strong financial performance, these three Cathie Wood stocks could provide generous returns. 
Via InvestorPlace
News headline image
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock ↗
On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technologies Inc. (NYSE:PLTR), and Nvidia Corp. 
Via Benzinga
News headline image
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. ↗
Recursion is playing the long game with its AI-focused approach to drug discovery and development. 
Via The Motley Fool
News headline image
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation ↗
They might not be profitable yet, but they're swinging for the fences. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AI Surge Ending: Only One Category Was Up This Week ↗
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? ↗
This stock's upside is huge, but so is its downside. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March ↗
No AI category went down in February, but 3 did in March - confirming my comment last week that 
Via Talk Markets
Topics Artificial Intelligence
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.